Kefclav 200mg/125mg Tablet is a combination antibiotic formulation containing Cefixime 200mg and Clavulanic Acid 125mg, designed to treat a broad spectrum of bacterial infections. Cefixime, a third-generation cephalosporin, exhibits bactericidal activity by inhibiting bacterial cell wall synthesis, effective against both Gram-positive and Gram-negative organisms. Clavulanic Acid acts as a beta-lactamase inhibitor, preventing enzymatic degradation of Cefixime by beta-lactamase-producing bacteria, thereby enhancing its antimicrobial efficacy. This synergistic combination is indicated for the treatment of respiratory tract infections, urinary tract infections, otitis media, skin and soft tissue infections, and other susceptible bacterial infections. Kefclav should be administered as per the prescribed dosage, typically once or twice daily, depending on the severity and type of infection. It is important to complete the full course of therapy to prevent resistance development. Common adverse effects may include gastrointestinal disturbances such as diarrhea, nausea, and abdominal discomfort. Hypersensitivity reactions are rare but require immediate medical attention. Caution is advised in patients with a history of penicillin or cephalosporin allergy. Renal function monitoring may be necessary in patients with impaired renal function. Kefclav 200mg/125mg Tablet offers an effective therapeutic option for managing resistant bacterial infections under medical supervision.